Roche silences Herceptin comparison

Share this article:

Biosimilar Herceptin is coming to India, but marketers will not be able to say so. The Wall Street Journal reported Friday that drugmaker Roche won a case that prevents the biosimilar manufacturer from using the brand name Herceptin in its marketing.

The decision also bars Biocon-Mylan from making comparisons between its lookalike breast cancer treatment's manufacturing processes, safety, efficacy and sales, with those of Herceptin.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.